AbbVie Inc ABBV Submits SKYRIZI Subcutaneous Crohns Regimen to FDA But NearTerm Upside Remains Capped By Competitive Risks What Kearny Financial KRNY segment performance reveals Kearny Financial Posts 2 EPS Miss Vs Analyst Ests SGP SpyGlass Pharma reports solid latestage trial progress lays out aggressive commercial expansion plans for 2025 BFC Bank First shares decline as Q1 earnings surprise misses Wall Street estimates by 195 percent